Natera (NASDAQ:NTRA – Get Free Report) and Anika Therapeutics (NASDAQ:ANIK – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, valuation, profitability and institutional ownership.
Institutional & Insider Ownership
99.9% of Natera shares are held by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are held by institutional investors. 5.1% of Natera shares are held by insiders. Comparatively, 12.1% of Anika Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Natera and Anika Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Natera | 2 | 2 | 17 | 2 | 2.83 |
| Anika Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
Natera currently has a consensus price target of $394.31, suggesting a potential upside of 35.87%. Anika Therapeutics has a consensus price target of $19.00, suggesting a potential upside of 42.67%. Given Anika Therapeutics’ higher probable upside, analysts clearly believe Anika Therapeutics is more favorable than Natera.
Profitability
This table compares Natera and Anika Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Natera | -5.66% | -8.61% | -5.93% |
| Anika Therapeutics | -1.43% | 1.87% | 1.39% |
Risk and Volatility
Natera has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500. Comparatively, Anika Therapeutics has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500.
Earnings & Valuation
This table compares Natera and Anika Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Natera | $2.91 billion | 14.47 | -$208.16 million | ($1.14) | -254.57 |
| Anika Therapeutics | $123.43 million | 1.45 | -$10.88 million | ($0.13) | -102.44 |
Anika Therapeutics has lower revenue, but higher earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Anika Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Anika Therapeutics beats Natera on 8 of the 15 factors compared between the two stocks.
About Natera
Natera, Inc. is a diagnostics company that develops and provides genetic testing and molecular diagnostics for reproductive health, oncology and organ health. Its tests analyze cell-free DNA and other genetic material to support screening, diagnosis and disease monitoring. In reproductive health, Natera offers Panorama, a noninvasive prenatal screening test, and Horizon, a carrier screening test. Its oncology portfolio includes Signatera, a personalized circulating tumor DNA test used to monitor for molecular residual disease and assess cancer recurrence.
About Anika Therapeutics
Anika Therapeutics is a medical technology company focused on orthopedic care and regenerative medicine. Founded in 1992 and headquartered in Bedford, Massachusetts, the company develops products using hyaluronic acid, a substance found naturally in the body and used in treatments for joint and tissue conditions. Its products include Orthovisc and Monovisc, injectable hyaluronic acid treatments for knee osteoarthritis. Anika also offers orthopedic products for areas such as sports medicine, joint preservation, and bone repair, including its Tactoset bone-void filler.
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
